Govt transfers AYUSH-64 drug technology to 46 Companies

"Earlier, only seven companies had the drug's license, which was used for the treatment of malaria.

150
Ayurvedic Govt
Representational image

Last Updated on November 22, 2021 by The Health Master

The Central Council for Research in Ayurvedic Sciences has transferred the technology of AYUSH-64, an effective drug in treating ‘mild and asymptomatic‘ and ‘mild to moderate‘ cases of C-19, to 46 companies.

“Earlier, only seven companies had the drug’s license, which was used for the treatment of malaria.

“After being found effective against the novel coronavirus infection during the pandemic outbreak, 39 new companies have been given fresh licenses, that is, the technology has been transferred to them,” a statement by the Ministry of AYUSH said.

AYUSH-64 has been developed by the Central Council for Research in Ayurvedic Sciences (CCRAS), the premier institution for research in Ayurveda under the AYUSH ministry.

The drug was developed in 1980 for the treatment of malaria. During the first wave of C-19 infection in March 2020, some scientific studies found it to be very effective in ‘mild and asymptomatic’ and ‘mild to moderate” infections of C-19.

It also has properties of fighting viruses, increasing body immunity and reducing fever, thus helping patients recover quickly.

During the first wave of C-19, a clinical trial was conducted by the AYUSH ministry and the Council of Scientific and Industrial Research (CSIR) wherein it was revealed that AYUSH-64 is a beneficial medicine for coronavirus patients.

So far, eight clinical trials have been conducted in which the drug was administered to 63,000 patients quarantined at home, and the drug was found beneficial.

There were also five random and two single studies in eight clinical trials, where patients were given only AYUSH-64, the statement said.

Before the first wave of C-19, seven companies, including IMPCL (the manufacturing unit of AYUSH ministry), were responsible for manufacturing the drug, but now the technology has been transferred to 39 companies, taking the total number of companies to 46, it said.

The latest move by CCRAS will lead to an increase in drug production and also make it easier to meet its demand.

The statement added that till date, no cases of side effects related to this medicine have been reported, yet experts suggest taking it only after consulting doctors.

Fake doctor arrested

Eli Lilly files litigation against 20 Indian Pharma Companies

Experts ask Govt to bring list of OTC Drugs

BDR Pharma launches Antibiotics to treat these infections

IPC to organize webinar on Key role of medical device industry…

Natco Pharma launches FDC Trifluridine & Tipiracil first time in India

Retired FDA officials are promoting Generic Drugs in innovative ways

No retention or renewal fees after one time registration of ASU products

International Conference on National Education Policy will be held at …

Latest Notifications regarding Pharmaceuticals

For informative videos by The Health Master, click on the below YouTube icon:

YouTube Icon
Telegram
WhatsApp
Facebook
LinkedIn
YouTube Icon
Google-news

Enter your email address:

Delivered by FeedBurner